Product Description
M-9140 is a Anti-CEACAM5 ADC for Advanced Solid Tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05464030)
Mechanisms of Action: CEACAM5 Antagonist
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan, Spain, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Adenocarcinoma|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Phase 1: Colorectal Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROCEADE PanTumor | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Adenocarcinoma|Gastrointestinal Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma |
2029-01-31 |
|
| jRCT2071240131 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2028-01-31 |
|
| PROCEADE-CRC-02 | P1 |
Recruiting |
Colorectal Cancer |
2026-05-25 |
|
| PROCEADE-CRC-01 | P1 |
Recruiting |
Colorectal Cancer |
2026-02-27 |